sion models were performed using the propensity scorematched cohorts. In these analyses, treatment with highdose ACE inhibitors and ARBs reduced mortality and CHF readmissions more than the medium-and low-dose treatments combined (Figure) .
1. Sleight P. The renin-angiotensin system: a review of trials with angiotensinconverting enzyme inhibitors and angiotensin receptor blocking agents. http: 2 Prior studies examining prescription pain reliever overdose deaths found that nonmedical use was common among decedents before death.
3,4 National estimates of past-year nonmedical use of these drugs, however, have remained stable since 2002. 5, 6 These estimates include the spectrum of nonmedical users from those who used pain relievers once or twice to those who were more frequent or chronic nonmedical users. This Research Letter attempts to determine if the subset of chronic nonmedical users of pain relievers-those using 200 days or more in the past year-has increased since 2002, in parallel with fatal overdoses of these drugs. Understanding trends in the frequency of nonmedical use can help identify populations at greatest risk for overdoses.
Methods. The National Survey on Drug Use and Health (NSDUH), an annual survey of the noninstitutionalized, civilian population 12 years and older, provides national estimates of substance use in the United States. Information on NSDUH survey methodology has been reported elsewhere. 6 Data from the NSDUH public use files were combined for years 2002-2003 and 2009-2010 to improve the detection of differences among specific subpopulations.
The NSDUH defines past-year nonmedical use (PYNMU) of prescription pain relievers as use in the prior 12 months without a prescription or use simply for the experience or feeling it causes. Drugs in this category include prescription opioid pain relievers and selected barbiturate combination products. Once respondents are identified as having PYNMU, they are asked to state the number of days they used pain relievers nonmedically in the past year.
Frequency of PYNMU of pain relievers was categorized into the following 4 groups: 1 to 29 days, 30 to 99 days, 100 to 199 days, and 200 to 365 days of nonmedical use. Annual average estimates of PYNMU for 2002-2003 and 2009-2010 were produced using SPSS version 19 Complex Samples (SPSS Inc) to account for sampling methods and weighting in the NSDUH. These estimates were then converted to rates of PYNMU per 1000 people 12 years and older. Two-tailed t tests were used to test significant differences between the periods in the annual average rates of frequency of PYNMU overall, by sex, and by age group. Statistical significance was determined at the P Ͻ.05 level. , while overall PYNMU did not change. This finding is important because it parallels increases in overdose deaths, treatment admissions, and other negative effects associated with opioid pain relievers in recent years. 1, 7 Variation in annual average rates of PYNMU among age groups and sex were also found. Some of the largest increases in PYNMU of 200 to 365 days were among male respondents (105.3%), and people aged 26 to 34 years (81.0%) and 35 to 49 years (134.6%). This is consistent with increases in overdose death rates for opioid pain relievers seen among these groups between 2002 and 2009. 8 An encouraging finding is the decrease in any PYNMU among people aged 12 to 17 years.
The finding that nearly 0.4% of people 12 years and older, almost 1 million people, reported using pain relievers nonmedically for 200 days or more in 2009-2010 and roughly 2%, or 4.6 million people, used them for 30 days or more is concerning. The annual average estimate of 613 million person-days of PYNMU implies that each of the 257 million opioid prescriptions dispensed in the United States annually contributes on average to more than 2 days of PYNMU. Coupled with continued increases in opioid pain reliever morbidity and mortality, these findings underscore the need for concerted public health and public safety action to prevent nonmedical use of these drugs. Interventions should focus on populations at greatest risk for chronic nonmedical use: men and persons aged 18 to 49 years. 1 For men younger than 75 years, the USPSTF maintained its previous recommendation: " . . . the evidence is insufficient to recommend for or against routine screening for prostate cancer. . . " 2(p915) (although this recommendation was changed to "do not screen" younger men in the 2011 guidelines). This study evaluates trends in prostate cancer incidence following the release of the 2008 USPSTF recommendation. If the revised recommendation led to a decline in prostate cancer screening rates, there should be a corresponding decline in the incidence of early-stage tumors among men 75 and older relative to trends in the incidence of late-stage tumors and early-stage tumors in younger men.
Methods. I measured trends in prostate cancer incidence rates by age group using the Surveillance, Epidemiology and End Results (SEER) 18 registry data, covering 28% of the US population. The SEER registries collect information on all newly diagnosed cancer cases in their respective catchment areas.
Prostate tumors were identified using International Classification of Diseases for Oncology version 3 code 619. I classified cases by stage at diagnosis using the derived American Joint Committee on Cancer summary stage variable: early (T1 or T2), late (T3 or T4), or unknown. I grouped patients into 3 age categories (30-64 years, 65-74 years, and 75 years and older). I calculated incidence rates per 100 000 persons, standardized within age categories by age (in 5-year age groups), race (white, black, American Indian, or other), and ethnicity (Hispanic or not Hispanic) to the 2009 population. I used an unpaired t test for proportions to assess the significance of differences in rates between years. The data were analyzed in Stata version 11 (StataCorp) statistical software. 
